康诺亚CD38单抗“CM313”实现对外授权康诺亚宣布,子公司与Timberlyne Therapeutics,Inc.(简称Timberlyne)达成独家授权许可协议。基于授权许可协议,康诺亚授予Timberlyne在全球(不包括中国)开发、生产及商业化靶向CD38的人源化单克隆抗体——CM313的独家权益。作为回报,康诺亚将获得3000万美元首付款和近期付款,并获得Timberlyne股权,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.